HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA After Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort

The aim of this study was to evaluate whether the presence of anti-hepatitis B (HBV) c antibodies (HBcAb positivity) could influence the control of Human Immunodeficiency Virus (HIV) viremia in patients living with HIV (PLWH) who switch a to two-drug antiretroviral therapy (2DR) containing lamivudin...

Full description

Bibliographic Details
Main Authors: Vincenzo Malagnino, Elisabetta Teti, Mirko Compagno, Luigi Coppola, Romina Salpini, Valentina Svicher, Monica Basso, Giuliana Battagin, Sandro Panese, Maria Cristina Rossi, Renzo Scaggiante, Daniela Zago, Marco Iannetta, Saverio Giuseppe Parisi, Massimo Andreoni, Loredana Sarmati
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Microorganisms
Subjects:
2DR
Online Access:https://www.mdpi.com/2076-2607/9/2/396